How to Get Rezdiffra (Resmetirom) in Connecticut

Rezdiffra: What Connecticut Patients Need to Know

Rezdiffra (resmetirom) is the first FDA-approved drug targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH. The FDA granted approval in March 2024 based on the MAESTRO-NASH trial, which demonstrated that 80 mg daily produced MASH resolution without worsening of fibrosis in 25.9% of participants versus 9.7% on placebo 1. Connecticut permits its prescription via both traditional office visits and telehealth encounters.

Resmetirom works as a thyroid hormone receptor beta (THR-β) agonist, selectively activating liver THR-β to reduce hepatic fat, inflammation, and fibrosis progression 2. For Connecticut residents with MASH, this represents a pharmacologic option where previously only lifestyle modification and off-label agents existed.

Eligibility Criteria for Rezdiffra in Connecticut

The FDA label restricts Rezdiffra to adults with noncirrhotic MASH and moderate to advanced hepatic fibrosis, corresponding to fibrosis stages F1b through F3 2. Connecticut payers, including Medicaid, apply these label restrictions during prior authorization review.

Diagnosis confirmation requires one of the following: liver biopsy showing NAFLD Activity Score (NAS) of 4 or greater with at least 1 point in each component (steatosis, ballooning, lobular inflammation), or validated noninvasive testing combining FIB-4 score above 1.3 with imaging evidence such as vibration-controlled transient elastography (VCTE) showing liver stiffness between 8.0 and 13.9 kPa 3. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance endorses sequential noninvasive testing for fibrosis staging in clinical practice 3.

Patients with decompensated cirrhosis (Child-Pugh B or C) are excluded. Those with active thyroid disease or TSH outside normal range require endocrine evaluation before initiation 2.

How to Get a Prescription in Connecticut

Connecticut law permits any physician (MD/DO), nurse practitioner (NP), or physician assistant (PA) holding an active Connecticut license and DEA registration to prescribe Rezdiffra. No specialty restriction exists at the state level, though most prescriptions originate from hepatology or gastroenterology practices.

Three pathways exist for Connecticut residents:

In-person specialist visit. Hartford, New Haven, and Stamford each have hepatology practices affiliated with academic medical centers. Yale New Haven Health and Hartford HealthCare both maintain liver clinics with providers experienced in MASH pharmacotherapy.

Primary care initiation. A PCP can prescribe Rezdiffra if they document appropriate fibrosis staging. The 2023 AASLD guidance supports primary care identification and treatment initiation for MASH when noninvasive tests confirm significant fibrosis 3.

Telehealth consultation. Connecticut's telehealth parity law (Public Act 21-9) requires insurers to cover telehealth visits at the same rate as in-person encounters 4. Licensed providers can evaluate, diagnose, and prescribe Rezdiffra via synchronous video visit without requiring an initial in-person encounter.

Telehealth Access for Rezdiffra in Connecticut

Connecticut residents do not need to visit a physical office to start resmetirom. A telehealth provider licensed in Connecticut can review existing imaging, lab work, and biopsy reports during a video consultation, then transmit the prescription electronically to a pharmacy.

The Connecticut Department of Public Health requires the prescribing provider to hold a valid Connecticut license regardless of their physical location 5. Interstate medical licensure compact membership simplifies this for providers in participating states.

For a telehealth-initiated Rezdiffra prescription, patients should have the following ready before the visit: recent liver imaging (FibroScan or MRI-PDFF within 6 months), FIB-4 score calculation, comprehensive metabolic panel, lipid panel, and thyroid function tests (TSH, free T4) 2. Uploading these to the telehealth platform before the appointment accelerates the encounter.

Required Labs Before Starting Rezdiffra

Prescribers in Connecticut must document baseline labs before initiating resmetirom. The FDA label mandates thyroid function monitoring given the drug's THR-β mechanism 2.

Baseline labs:

• Hepatic panel (AST, ALT, GGT, alkaline phosphatase, total bilirubin, albumin)
• Complete blood count
• FIB-4 index (calculated from age, AST, ALT, platelet count)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• TSH and free T4
• HbA1c (most MASH patients have concurrent type 2 diabetes or prediabetes)

Monitoring schedule: The label recommends hepatic function assessment at baseline, month 3, and every 6 months thereafter. Discontinue if ALT or AST rises above 5 times the upper limit of normal 2. In MAESTRO-NASH, ALT reductions of 35-40% from baseline occurred by week 24 in the 80 mg group, confirming hepatic pharmacologic activity 1.

Connecticut Quest Diagnostics and LabCorp locations can process all required panels. Some telehealth platforms partner with mobile phlebotomy services that draw labs at the patient's home.

Prior Authorization in Connecticut

Connecticut Medicaid and most commercial plans require prior authorization (PA) for Rezdiffra. The PA process typically takes 3-7 business days.

Documentation required for PA submission:

• Confirmed MASH diagnosis with fibrosis stage (F1b, F2, or F3)
• Method of fibrosis staging (biopsy pathology report OR FibroScan with FIB-4)
• Evidence that lifestyle modification (diet, exercise) was attempted for at least 6 months
• Baseline hepatic function tests
• Documentation of BMI and metabolic comorbidities
• Prescriber specialty and clinical rationale

Connecticut Medicaid's preferred drug list updated in 2024 to include Rezdiffra with step therapy requiring documented lifestyle intervention failure 6. Commercial insurers including Anthem, Aetna, and ConnectiCare each maintain individual PA criteria, but all reference the FDA-labeled indication.

If PA is denied, Connecticut law requires insurers to provide an expedited external review within 72 hours for urgent cases. The AASLD position statement emphasizes that fibrosis progression in MASH occurs at a median rate of one stage per 7.1 years, supporting the clinical urgency argument for patients at F2 or F3 7.

Pharmacy Options in Connecticut

Once PA is approved, Rezdiffra can be dispensed through three channels in Connecticut:

Specialty pharmacies. Most insurers route Rezdiffra through designated specialty pharmacy networks. CVS Specialty, Accredo (Express Scripts), and OptumRx Specialty all carry resmetirom in their formularies. Ship-to-home delivery is standard, typically arriving within 5-7 business days after PA approval.

503A compounding pharmacies. Connecticut-licensed 503A pharmacies can compound resmetirom preparations when a patient-specific prescription exists. The Connecticut Department of Consumer Protection regulates these facilities under state pharmacy law 8. This route may offer cost advantages for uninsured patients, though compounded preparations are not FDA-evaluated for bioequivalence.

Retail specialty. Select retail pharmacies with specialty designations can stock and dispense Rezdiffra directly. Patients should call ahead to confirm availability, as not all locations maintain inventory.

Cost and Insurance Coverage in Connecticut

Rezdiffra's wholesale acquisition cost (WAC) is approximately $47,400 annually for the 80 mg dose. Actual patient cost varies significantly by insurance status.

Connecticut Medicaid: Covered with PA. Copay capped at $3.50 per prescription for most beneficiaries per Connecticut Medicaid pharmacy benefit rules 6.

Commercial insurance: Typical specialty tier copays range from $50-$150/month with manufacturer copay assistance. Madrigal Pharmaceuticals operates a patient support program (Rezdiffra Connect) that may reduce out-of-pocket costs to $0 for commercially insured patients meeting income criteria 9.

Medicare Part D: Coverage varies by plan. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) limits Medicare beneficiary exposure regardless of drug cost 10.

Uninsured patients: Madrigal's patient assistance program and 503A compounding represent the two primary cost-reduction pathways. Hospital-based financial assistance programs at Yale New Haven and Hartford Hospital may also apply.

Clinical Expectations: What Rezdiffra Does

Patients starting resmetirom should understand the expected timeline. In MAESTRO-NASH, statistically significant LDL reduction (-13.6%) and triglyceride reduction (-20.1%) appeared by week 12 in the 80 mg group 1. Liver fat reduction measured by MRI-PDFF reached approximately 45% relative decrease by week 52 1.

The primary endpoint of fibrosis improvement by at least one stage without NASH worsening was met by 25.9% on 80 mg versus 9.7% placebo at 52 weeks (P<0.001) 1. NASH resolution without fibrosis worsening occurred in 29.9% on 80 mg versus 9.7% on placebo 1.

Common adverse events included diarrhea (27% vs 19% placebo) and nausea (22% vs 14% placebo), generally mild and self-limiting within the first 4-8 weeks 2. No gallbladder-related safety signals emerged at rates above placebo, distinguishing resmetirom from GLP-1 receptor agonists 11.

Transferring a Rezdiffra Prescription to Connecticut

Patients relocating to Connecticut or obtaining prescriptions from out-of-state providers can transfer their Rezdiffra prescription. Connecticut accepts prescription transfers from any US-licensed pharmacy under state Board of Pharmacy regulations 8.

The receiving pharmacy contacts the originating pharmacy to verify the prescription. PA may need resubmission if the patient's insurance changes during relocation. Patients should request a copy of all supporting documentation (imaging reports, biopsy results, lab history) from their previous provider to support PA at the new plan.

For patients whose out-of-state provider holds a Connecticut license (or interstate compact membership), the original prescriber can continue managing the patient via telehealth without transfer, simply routing the prescription to a Connecticut pharmacy.

Concurrent Therapies and Monitoring

Resmetirom is often prescribed alongside other metabolic therapies. Drug interaction data from the FDA label notes that resmetirom increases statin exposure modestly; the label recommends monitoring for statin-related myopathy 2. A 2023 meta-analysis confirmed that combination of THR-β agonism with statin therapy produces additive LDL lowering without excess hepatotoxicity signals 12.

For Connecticut patients already on GLP-1 receptor agonists for concurrent obesity or type 2 diabetes, no pharmacokinetic interaction with resmetirom has been identified. The MAESTRO-NASH trial permitted concurrent metformin, pioglitazone, and vitamin E use 1.

Ongoing monitoring in Connecticut should include FibroScan or equivalent elastography at 12-month intervals to assess treatment response. The European Association for the Study of the Liver (EASL) recommends repeat noninvasive assessment annually during MASH pharmacotherapy 13.

Connecticut-Specific Regulatory Considerations

Connecticut's scope-of-practice laws allow NPs to prescribe Rezdiffra independently under APRN full practice authority (Connecticut General Statutes § 20-87a) 14. PAs prescribe under collaborative agreement with a supervising physician but are not restricted from specialty medications.

The Connecticut Insurance Department mandates coverage parity for telehealth-prescribed medications, meaning insurers cannot deny Rezdiffra solely because the prescribing encounter occurred virtually 4. This protection extends to both state-regulated fully insured plans and Connecticut Medicaid managed care organizations.

Patients enrolled in Connecticut's HUSKY Health (Medicaid) program access Rezdiffra through the Medicaid pharmacy benefit with standard PA requirements. The state's 2024 formulary update classified resmetirom as a non-preferred specialty agent requiring clinical PA 6.